Tisotumab  (Synonyms: Anti-Human F3 Recombinant Antibody)

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used for the research of solid tumors^[1].

Tisotumab (0.5 mg, 30 min before incubation of cells with tiso-IR700) blocks IR700 fluorescence signal in A431 and HPAF-II cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tisotumab (DIG-labeled, infused) is delivered to the tumor tissue and then bound to the surface of HPAF-II tumors in HPAF-II tumor bearing mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1418628-81-5

Liquid

Colorless to light yellow

[Tisotumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Tissue Factor Protein, Human can bind Tisotumab. The EC₅₀ for this effect is 10.79 ng/mL.

• [1]. Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22(5):609-619.  [Content Brief]

  [2]. Takao S, et al. Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies. Cancer Immunol Immunother. 2025 Jan 3;74(2):48.  [Content Brief]